Furthermore, this study emphasizes the clinical vulnerability of individuals with germline RUNX1-FPDMM—as well as those with other thrombocytopenia-associated predispositions such as ETV6 or ANKRD26—and underscores the need for dedicated healthcare infrastructure. This evidence concerns the gene ANKRD26 and Thrombocytopenia.